Global Health Limited
₹1,269.05-₹30.15 (-2.3%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹31,404 Cr
- P/E
- 59.8x
- EV / EBITDA
- 37.3x
- Revenue
- ₹3,204 Cr
- Net margin
- 16.3%
- ROCE
- 21.8%
Price chart
Technical chartScreen technicals →-7.5% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -7.0%
- 3M
- -10.4%
- 6M
- +13.5%
- 1Y
- -7.5%
- 5Y
- +206.7%
52-week range
Day change -₹30.15 (-2.3%) from ₹1,299 to ₹1,269 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in MEDANTA, bought on each weekday since 2022.
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 15.1%
Concerns1
- Negative free cash flow (₹110 Cr)
Rule-based from financial data. Not advice.
About the company
Global Health Limited, together with its subsidiaries, provides healthcare services in India.
Read moreShow less
Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.
- Sector
- Healthcare
- Shares outstanding
- 26.9 Cr shares
- ISIN
- INE474Q01031
- BSE code
- 543654
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹31,404 Cr
- P/E
- 59.8x
- P/B
- 8.3x
- EV / EBITDA
- 37.3x
- EV / Sales
- 10.6x
- P/S
- 10.6x
- Earnings yield
- 1.7%
- 52-week high
- ₹1,512.60
- 52-week low
- ₹961.75
Profitability
- Operating margin
- 25.3%
- Net margin
- 16.3%
- EBITDA margin
- 28.4%
- ROE
- 16.0%
- ROCE
- 21.8%
- ROA
- 12.2%
- Dividend payout
- 0.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 13.8%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹3,204 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 7.7%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 15.1%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹844 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 79.6%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -4.9%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 36.4%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹559 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 29.7%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹205 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 25.3%
Solvency and efficiency
- Current ratio
- 3.94
- Debt / Equity
- 0.14
- Debt / Assets
- 0.11
- Debt / EBITDA
- 0.50
- Interest coverage
- 14.76
- Financial leverage
- 1.31
- CFO / Net profit
- 1.15
- Cash / Market cap
- 5.4%
- Cash per share
- ₹63.15
- Asset turnover
- 0.75
- Fixed asset turnover
- 1.81
- Capital intensity
- 0.55
- Debtor days
- 26 days
- Inventory turnover
- 12.59
- Cash conversion cycle
- -29 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹14 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹2,432 Cr |
| Sales | Operating profit | ₹772 Cr |
| Operating profit | Interest | ₹41 Cr |
| Operating profit | Depreciation | ₹150 Cr |
| Operating profit | Profit before tax | ₹581 Cr |
| Other income | Profit before tax | ₹41 Cr |
| Profit before tax | Tax and other | ₹161 Cr |
| Profit before tax | Net profit | ₹462 Cr |
Revenue and net profit
Revenue grew 7.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹1,227 Cr | ₹57 Cr |
| FY2022 | ₹1,765 Cr | ₹219 Cr |
| FY2023 | ₹1,974 Cr | ₹263 Cr |
| FY2024 | ₹2,975 Cr | ₹486 Cr |
| FY2025 | ₹3,204 Cr | ₹462 Cr |
Cash flows
FY2025: ₹528 Cr from operations, -₹110 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹201 Cr | -₹49 Cr |
| FY2022 | ₹235 Cr | -₹78 Cr |
| FY2023 | ₹431 Cr | ₹174 Cr |
| FY2024 | ₹559 Cr | ₹40 Cr |
| FY2025 | ₹528 Cr | -₹110 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹3,204 Cr+7.7%1Y
- Net profit
- ₹462 Cr-4.9%1Y
- Cash from operations
- ₹528 Cr
- Free cash flow
- -₹110 Cr-375.0%1Y
- Revenue CAGR, 5Y
- 15.1%
- EBITDA CAGR, 5Y
- 26.4%
- Net profit CAGR, 5Y
- 36.4%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹3,204 Cr | ₹772 Cr | — | ₹462 Cr | ₹528 Cr | -₹110 Cr | 13.2% | +7.7% | -4.9% |
Monthly returns
Month-by-month returns of MEDANTA across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹4,441 Cr |
| Equity capital | ₹54 Cr |
| Reserves | ₹3,444 Cr |
| Borrowings | ₹337 Cr |
| Other liabilities | ₹606 Cr |
| Assets | ₹4,441 Cr |
| Fixed assets | ₹1,861 Cr |
| Capital work in progress | ₹458 Cr |
| Investments | ₹366 Cr |
| Other assets | ₹1,757 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
MEDANTA trades at 59.8x earnings against a peer median of 52.6x (a 14% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Global Health LimitedMEDANTAthis companyP/E ↑ premium | ₹31,404 Cr | 59.8x | 8.3x | 16.0% | 37.3x |
| Narayana Hrudayalaya LimitedNH | ₹38,566 Cr | 83.0x | 16.6x | 23.1% | 54.0x |
| Ipca Laboratories Ltd.IPCALAB | ₹38,240 Cr | 39.5x | 5.2x | 8.3% | 32.5x |
| Anthem Biosciences LimitedANTHEM | ₹35,376 Cr | 66.2x | 12.4x | 19.4% | 61.4x |
| Ajanta Pharma Ltd.AJANTPHARM | ₹34,058 Cr | 35.8x | 8.3x | 23.6% | 27.3x |
| Aster DM Healthcare LimitedASTERDM | ₹31,356 Cr | 92.8x | 7.1x | 5.4% | 78.2x |
| Emcure Pharmaceuticals LimitedEMCURE | ₹29,399 Cr | 67.9x | 9.1x | 8.3% | 53.5x |
| J.B. Chemicals & Pharmaceuticals LtJBCHEPHARM | ₹29,217 Cr | 41.5x | 7.9x | 18.8% | 32.1x |
| Gland Pharma LimitedGLAND | ₹28,321 Cr | 24.5x | 2.8x | 11.6% | 17.3x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
MEDANTA since 1 January, against earlier years.
Historical volatility
MEDANTA's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 14.0% |
| FY2022 | 22.0% |
| FY2023 | 21.0% |
| FY2024 | 25.0% |
| FY2025 | 24.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹3,204 Cr |
| Costs | |
| Interest | ₹41 Cr |
| Expenses | ₹2,432 Cr |
| Operating profitOperating Profit | ₹772 Cr |
| Other income and charges | |
| Profit before tax | ₹623 Cr |
| Tax | |
| Net profitNet Profit | ₹462 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹4,441 Cr |
| Equity capitalEquity Capital | ₹54 Cr |
| Reserves | ₹3,444 Cr |
| Borrowings | ₹337 Cr |
| Other liabilitiesOther Liabilities | ₹606 Cr |
| AssetsTotal Assets | ₹4,441 Cr |
| Fixed assetsFixed Assets | ₹1,861 Cr |
| Capital work in progressCWIP | ₹458 Cr |
| Investments | ₹366 Cr |
| Other assetsOther Assets | ₹1,757 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹528 Cr |
| Investing cash flowCash from Investing Activity | -₹638 Cr |
| Financing cash flowCash from Financing Activity | -₹94 Cr |
| Change in cashNet Cash Flow | -₹205 Cr |
Learn while you research
Academy chapters picked for Global Health Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 59.8, learn when high multiples are justified.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read